Ordering information regarding a Cardiolipin Antibody, IgM test for Clinical Diagnostic Laboratories. Cardiolipin Antibody, IgM Ordering Recommendation Acceptable initial test when antiphospholipid syndrome (APS) is highly suspected. Order with Lupus Anticoagulant Reflexive Panel (0030181 ) and Beta-2 Glycoprotein 1 Antibodies, IgG and IgM (0050321 ). Cardiolipin Antibodies, IgG and IgM (0099344 ) is preferred. Mnemonic AC-IGM Performed Mon-Sat Methodology Semi-Quantitative Enzyme-Linked Immunosorbent Assay Reported 1-2 days New York DOH Approval Status This test is New York DOH approved. Specimen Required Patient Preparation: Collect: Serum separator tube. Specimen Preparation: Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to a Standard Transport Tube. (Min: 0.3 mL) Storage/Transport Temperature: Refrigerated. Unacceptable Conditions: Plasma or other body fluids. Contaminated, heat-inactivated, hemolyzed, or lipemic specimens. Remarks: Stability: After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year Reference Interval <=12 MPL Negative 13-19 MPL Indeterminate 20-80 MPL Low to Moderately Positive 81 MPL or above High Positive Interpretive Data The persistent presence of IgG and/or IgM cardiolipin (CL) antibodies in moderate or high levels (greater than 40 GPL and/or greater than 40 MPL units) is a laboratory criterion for the diagnosis of antiphospholipid syndrome (APS). Persistence is defined as moderate or high levels of IgG and/or IgM CL antibodies detected in two or more specimens drawn at least 12 weeks apart (J Throm Haemost. 2006;4:295-306). Lower positive levels of IgG and/or IgM CL antibodies (above cutoff but less than 40 GPL and/or less than 40 MPL units) may occur in patients with the clinical symptoms of APS; therefore, the actual significance of these levels is undefined. Results should not be used alone for diagnosis and must be interpreted in light of APS-specific clinical manifestations and/or other criteria phospholipid antibody tests. Compliance Category: FDA Note MPL = IgM phospholipid units CPT Code 86147 Components Component Chart Name Cardiolipin Antibody IgM Component Test Code 0050902 LOINC 3182-3 Aliases ACA aCL aCL Antibody aCL IgG Anti-Cardiolipin Anticardiolipin Anticardiolipin Antibodies Cardiolip

Ordering information regarding an ACTH test for Clinical Diagnostic Laboratories. ACTH by Immunohistochemistry Ordering Recommendation Mnemonic Methodology Immunohistochemistry Performed Mon-Sat Reported 1-3 days New York DOH Approval Status This test is New York DOH approved. Specimen Required Patient Preparation: Formalin fix (10 percent neutral buffered formalin) and paraffin embed specimen (cells must be prepared into a cellblock). Protect paraffin block and/or slides from excessive heat. Transport tissue block or 5 unstained (3- to 5-micron thick sections), positively charged slides in a tissue transport kit Collect: Tissue or Cells Specimen Preparation: After drawing blood into an EDTA tube, label it with the patient's details. Keep the specimen at room temperature (15-30°C) if transporting within a few hours. For longer transport, place it in a biohazard bag within a cooler with ice packs, maintaining 2-8°C. Deliver it to the lab within 24 hours. Storage/Transport Temperature: Room temperature or refrigerated. Ship in cooled container during summer months. Unacceptable Conditions: Specimens submitted with non-representative tissue type. Depleted specimens. Remarks: Stability: Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable Reference Interval Components Available Separately Reference Interval Interpretive Data Note This test is performed as a stain and return (technical) service only. CPT Code 88342 Components Component Test Code 2003428 2003429 Component Chart Name ACTH by IHC LOINC ACTH Reference Number 94736-6 Aliases ACTH ACTH Antibody Staining ACTH by IHC

Did you have a test with Clinical Diagnostic Laboratories? Check here to access your results. Patient Test Results If you provided a doctor's order/referral, your results will be delivered to your physician either via fax or via their portal (if they have established an account with us). If you did not provide an order/referral, your results will be sent to you directly via email in the form of a PDF file. Patients are able to request a copy of their results at any time. If you'd like to request a copy of your lab results, please contact us using the button below. Email Us About Lab Results

The product page for the Respiratory Panel for Clinical Diagnostic Laboratories. Complete Respiratory Allergy Scan Breathe easier with answers. This panel is designed to identify airborne allergens that may be behind your sneezing, congestion, itchy eyes, or asthma-like symptoms. Whether it’s seasonal discomfort or year-round sensitivity, this test helps pinpoint the specific environmental triggers affecting your respiratory health. Here’s what it checks — and why it matters: IgE Total, Serum – Measures your body’s overall allergic sensitivity, giving a baseline for reactivity. Environmental & Airborne Allergens – Tests for 23 common respiratory irritants, including: Molds: Alternaria Alternata, Aspergillus Fumigatus, Cladosporium Herbarum, Penicillium Chrysogenum Grasses & Weeds: Bermuda Grass, Johnson Grass, Timothy Grass, Rough Pigweed, Common Ragweed Trees & Pollens: Mountain Cedar, Birch, Cottonwood, Elm, Maple (Box Elder), Oak White, Pecan Hickory, Sheep Sorrel Animals: Cat Dander, Dog Dander, German Cockroach, Mouse Urine Other: Dernariohagoides (Dust Mite), White Mulberry From mold spores to pet dander and pollen, this test helps you understand exactly what’s causing your symptoms — so you can take smart steps to avoid triggers, improve your indoor air quality, and feel more comfortable year-round. Fast results, no referral needed, and no guesswork. $288.00 Taxes will be calculated at checkout Buy Now

This is the home page to access the Patient Portal. The patient portal allows previous and returning patients the ability to access their lab results. Your Health, One Click Away View Your Lab Results anytime, anywhere—fast, secure, and easy to use I don't have a portal set up yet and need access I have a portal setup and I'm logging in Your Lab Results, All in One Place Our new Patient Portal gives you instant access to your laboratory test results. Whether you're tracking progress, reviewing past reports, or preparing for your next visit, everything you need is now at your fingertips. Safe, secure, and always available. Sign Up for Portal Access Why Use the Patient Portal? Simple Access, Meaningful Insights 📊 Track your results over time for better health insight 🔐 Secure, private access to your lab data 📥 View current and past lab reports 🧾 Compare individual test results from different visits ✅ Set up in just a few minutes with your email How to Get Access Getting Started is Easy —Just Follow These Steps We’ll confirm your email and send you a secure sign-up link. You’ll create a password and verify your account. Log in anytime from the Patient Portal page to view your test results and trends. Contact Us to Get Started

The Privacy Policy of Clinical Diagnostic Laboratories located in Sterling and Ashburn is located on this page. Privacy Statement 1. Introduction Welcome to Clinical Diagnostic Laboratories ("we," "us," or "our"). This Privacy Statement outlines how we collect, use, disclose, and safeguard your personal and medical information when you use our services, including our website and related applications (collectively referred to as the "Services"). By using our Services, you consent to the practices described in this Privacy Statement. 2. Information We Collect We may collect various types o f information from you, including: Personal Information: Name, contact information, date of birth, and other relevant identifiers. Medical Information: Information related to your health, medical history, and test results. Payment Information: Payment details for services purchased through our platform. Usage Data: Information about how you use our Services, including website interactions and app usage. 3. How We Use You r Infor mation We use the collected information for the following purposes: Providing Services: To deliver and manage the diagnostic testing services you request, including appointment scheduling and test result delivery. Communication: To contact you regarding appointments, test results, billing, and other relevant matters. Improving Services: To enhance and customize your experience with our Services, and to develop new features and offerings. Legal and Regulatory Compliance: To comply with applicable laws, regulations, and legal processes. 4. Information Sharing We may share your information with: Healthcare Providers: To facilitate the interpretation and communication of test results by qualified medical professionals. Service Providers: Third-party vendors and partners who assist us in providing and maintaining our Services. Legal Authorities: When req uired by law or in response to legal requests, such as court orders or subpoenas. 5. Data Security We implement appropriate technical and organizational measures to safeguard your personal and medical information. However, no data transmission over the Internet is completely secure, and we cannot guarantee the absolute security of your information. 6. Your Choices Access and Correction: You may review, update, or correct your personal information by contacting us. Communications: You can choose to receive or opt out of certain communications from us. Cookies and Tracking: You can manage your cookie preferences through your browser settings. 7. Third-Party Links Our Services may contain links to third-party websites. We are not responsible for the privacy practices or content of these websites. Please review the privacy policies of third-party sites before providing any personal information. 8. Children's Privacy Our Services are not intended for individuals un der the age of 18. We do not knowingly collect personal information from children. 9. Changes to this Privacy Statement We may update this Privacy Statement to reflect changes in our practices or legal requirements. Any changes will be posted on our website, and the date of the latest revision will be indicated. 10. Contact Us If you have questions, concerns, or requests related to your privacy or this Privacy Statement, please contact us at: Clinical Diagnostic Laboratories 2 Pidgeon Hill Dr., Suite 150, Sterling, VA 20165 44355 Premier Plaza, Suite 240, Ashburn, VA 20147 Email: info@clinicaldiagnosticlab.com Phone: (703) 430-1111 Fax: (703) 722-3890

Ordering information regarding an Ammonia for Clinical Diagnostic Laboratories. Ammonia, Plasma Ordering Recommendation Evaluate status of existing liver disease. Monitor treatment in patients with inborn errors of metabolism. Methodology Enzymatic Assay Performed Mon-Sat Reported Within 24 hours New York DOH Approval Status This test is New York DOH approved. Specimen Required Patient Preparation: Collect: Green (sodium or lithium heparin). Collect on ice. Specimen Preparation: Separate plasma from cells and freeze within 15 minutes of draw time. Specimens need to be spun in a refrigerated centrifuge. Transfer 2 mL plasma to a standard Transport Tube. (Min: 0.25 mL) Storage/Transport Temperature: CRITICAL FROZEN. Separate specimens must be submitted when multiple tests are ordered. Unacceptable Conditions: Serum or blood. Non-frozen specimens. Specimens containing oxalate or citrate Remarks: Stability: After separation from cells: Ambient: Unacceptable; Refrigerated: 2 hours; Frozen: 3 weeks (do not thaw) Reference Interval 0-14 days 95 µmol/L or less 15 days-6 years 68 µmol/L or less Greater than 6 years 72 µmol/L or less Interpretive Data Note CPT Code 82140 Components Component Test Code Component Chart Name LOINC 0020043 Ammonia, Plasma 16362-6 Aliases NH3 Plasma ammonia level

Ordering information regarding a Double-Stranded DNA (DsDNA) Antibody test for Clinical Diagnostic Laboratories. Double-Stranded DNA (DsDNA) Antibody Ordering Recommendation Secondary screening for systemic lupus erythematosus (SLE) based on ANA results. Mnemonic Methodology Semi-Quantitative Enzyme-Linked Immunosorbent Assay/Semi-Quantitative Indirect Fluorescent Antibody Performed Mon-Sat Reported 1-3 Days New York DOH Approval Status This test is New York DOH approved. Specimen Required Patient Preparation: Collect: Serum separator tube (SST). Specimen Preparation: Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to a Standard Transport Tube. (Min: 0.5 mL) Storage/Transport Temperature: Refrigerated Unacceptable Conditions: Plasma. Contaminated, hemolyzed, or severely lipemic specimens. Remarks: Stability: After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month (avoid repeated freeze/thaw cycles) Reference Interval 24 IUs or less Double-Stranded DNA (dsDNA) Ab IgG ELISA Interpretive Data Positivity for anti-double stranded DNA (anti-dsDNA) IgG antibody is a diagnostic criterion of systemic lupus erythematosus (SLE). Specimens are initially screened by enzyme-linked immunosorbent assay (ELISA). If ordered as reflex (0050215), positive ELISA results (>24 IU) will be reflexed to a highly specific IFA titer (Crithidia luciliae indirect fluorescent test [CLIFT]) for confirmation. Some patients with early or inactive SLE may be positive for anti-dsDNA IgG by ELISA but negative by CLIFT. If the patient is negative by CLIFT but positive by ELISA and clinical suspicion remains, consider antinuclear antibody (ANA) testing by IFA. Note If dsDNA IgG antibody is detected, the result will be confirmed by Double-Stranded DNA (dsDNA) Antibody, IgG by IFA (using Crithidia luciliae). Additional charges apply. CPT Code 86225; if reflexed, add 86256 Components Component Chart Name Component Test Code LOINC Double-Stranded DNA (dsDNA) Ab IgG ELISA 0050215 58465-6 Aliases anti-DNA Anti-dsDNA Antibody Anti-Native DNA Antibody to ds-DNA Crithidia luciliae DNA ds Ab Double stranded DNA antibody ds DNA Ab ds-DNA ds-DNA IgG dsDNA reflex dsDNA reflex panel Native double-stranded DNA antibody

Ordering information regarding a Tryptase test for Clinical Diagnostic Laboratories. SARS-CoV-2 (COVID-19) Ordering Recommendation Use to detect the novel coronavirus (SARS-CoV-2). Mnemonic Methodology Qualitative Nucleic Acid Amplification (NAA) Performed Mon-Sat Reported 1-2 days New York DOH Approval Status This test is New York DOH approved. Specimen Required Patient Preparation: Collect: Nasopharyngeal swab, oropharyngeal swab, nasal swab, or saliva. To ensure the highest quality results, a nasopharyngeal swab is recommended. Specimen Preparation: Nasopharyngeal swab: Place in viral transport media Liquid Amies, or saline (minimum volume 1.2mL). Place each specimen in an individually sealed bag. Oropharyngeal or nasal swab: Place in viral transport media Liquid Amies, or saline (minimum volume 1.2mL). Swab Collection Kit. Place each specimen in an individually sealed bag. Saliva: Transport in COVID-19 Saliva Collection Tube Storage/Transport Temperature: Frozen. Unacceptable Conditions: Undiluted saliva. Saliva submitted in anything other than a Saliva Collection Tube. Swabs not in media. Wood swabs, calcium alginate swabs. Media with guanidine-containing materials, 'molecular media' that indicates inactivation of pathogens and preservation of RNA/DNA, charcoal media. Specimens sent in tubes with pop-top lids/caps. Specimens in glass tubes. Remarks: Stability: Swabs: Ambient: Unacceptable; Refrigerated: 2 days; Frozen: 1 month Saliva: Ambient: 5 days; Refrigerated: 5 days, Frozen: 5 days Reference Interval Interpretive Data This test should be ordered for the detection of the 2019 novel coronavirus SARS-CoV-2 in individuals who meet SARS-CoV-2 clinical and/or epidemiological criteria. The Coronavirus SARS-CoV-2 (COVID-19) by nucleic acid amplification test is for in vitro diagnostic use under the FDA Emergency Use Authorization (EUA) for U.S. laboratories certified under CLIA to perform high complexity tests. Not Detected results do not rule out the presence of PCR inhibitors in the patient specimen or assay-specific nucleic acid in concentrations below the level of detection by the assay. Detected results are indicative of the presence of SARS-CoV-2 RNA. Due to the complexity of nucleic acid amplification methodologies, there may be a risk of false-positive results. Clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Reliable results are dependent on adequate specimen collection, transport, storage, and handling. Compliance Category: Depends on Specimen/Source/Method Note CPT Code 87635 Components Component Chart Name SARS-CoV-2 Source Component Test Code 3002639 LOINC 31208-2 3002640 SARS-CoV-2 by NAA 94500-6 Aliases 2019-nCoV Coronavirus disease - 2019 COVID-19 COVID-19 Illness COVID-2019 SARS-CoV-2

Ordering information regarding Carbamazepine, Free and Total, Serum or Plasma for Clinical Diagnostic Laboratories. Carbamazepine, Free and Total, Serum or Plasma Ordering Recommendation Optimize drug therapy and monitor patient adherence. Methodology Quantitative Enzyme Multiplied Immunoassay Technique Performed Mon-Sat Reported 1-5 Days New York DOH Approval Status This test is New York DOH approved. Specimen Required Patient Preparation: Collect: Serum Pre-dose (Trough) Draw - At a Steady State Concentration in Plain Red. Specimen Preparation: Separate from cells ASAP or within 2 hours of collection. Transfer 2 mL serum to a Standard Transport Tube. (Min: 1 mL) Storage/Transport Temperature: Refrigerated. Unacceptable Conditions: Whole Blood, Citrated Plasma. Tubes that contain liquid anticoagulant.or Serum separator tube (SST). Remarks: Stability: Ambient: 5 days; Refrigerated: 5 days; Frozen: 3 months Reference Interval Test Number Components Reference Interval Total Carbamazepine Free Carbamazepine Therapeutic Range: 4.0-12.0 µg/mL Toxic Range: Greater than 15 µg/mL Therapeutic Range: 1.0-3.0 µg/mL Toxic Range: Greater than 3.8 µg/mL Percent Free Carbamazepine 8.0-35.0% Interpretive Data The therapeutic range is based on serum pre-dose (trough) draw at steady-state concentration. Free carbamazepine may be important to monitor in patients with altered or unpredictable protein binding capacity. Carbamazepine is also subject to drug-drug interactions due to displacement of protein binding and extensive metabolism. Cross-reactivity with metabolites may account for differences in carbamazepine among analytical methods. Calculating percent free attempts to minimize differences in assay cross-reactivity and may be useful in dose optimization. A rare adverse drug reaction to carbamazepine therapy includes Stevens-Johnson syndrome or toxic epidermal necrolysis. Patients of Asian ancestry with the presence of the HLA-B*15:02 have an increased risk for this carbamazepine-induced life-threatening reaction. Pharmacogenetic testing for HLA-B*15:02 is recommended for patients at risk for carbamazepine hypersensitivity prior to treatment. This information has been included in the FDA-approved label for carbamazepine (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm) and guideline from the Clinical Pharmacogenetics Implementation Consortium (https://www.pharmgkb.org/guidelines). A combination of therapeutic drug monitoring with HLA-B*15:02 pharmacogenetics genotyping may benefit patients who are at increased risk for developing carbamazepine-induced adverse events due to rare genotypes other than HLA-B*15:02 variant allele. Note CPT Code 80156; 80157 Components Component Test Code Component Chart Name LOINC 2011768 Free Carbamazepine 3433-0 2011769 Percent Free Carbamazepine 32852-6 2011770 Total Carbamazepine 3432-2 Aliases Atretol Biston Calesin Carbamazepin, Free Carbatrol Epimaz Epitol Epitrol Equetro Finlepsin Free Carbamazepine Free Tegretol Protein Free Carbamazepine Sirtal Tegretol, Free Telesmin